Home › Langerhans-Cell Histiocytosis › Texas
Langerhans-Cell Histiocytosis clinical trials in Texas
4 studies for Langerhans-Cell Histiocytosis are looking for participants at sites in Texas.
Cities in Texas
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- Dell Children's Medical Center of Central Texas, Austin
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- El Paso Children's Hospital, El Paso
- and 6 more
RecruitingPhase 2
180 Days – 22 Years · All sexes · Updated Oct 2, 2026 · NCT05828069Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
- Cook Children's Health Care System, Fort Worth
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Apr 7, 2026 · NCT06582745Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
- Children's Medical Center- UTSW, Dallas
- Texas Children's Hospital, Houston
RecruitingPhase 2
All ages · All sexes · Updated Sep 18, 2025 · NCT04079179Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- Dell Children's Medical Center, Austin
- Cook Children's Health Care System, Fort Worth
- Texas Children's Hospital, Houston
- and 2 more
RecruitingPhase 3
Up to age 21 · All sexes · Updated Sep 11, 2025 · NCT02670707From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.